Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Creon

Allergan logo

Allergan sues Valeant and Pershing for insider trading

Botox manufacturer alleges hedge fund fraudulently built up stake in the company

Allergan logo

Allergan wields axe to fend off Valeant

Plans to cut 1.500 jobs in sign of independence

Allergan logo

Pershing mounts assault on Allergan board

Proposes new directors to secure Valeant takeover

Allergan logo

Allergan will start phase III DARPin trials next year

Will investigate drug in wet age-related macular degeneration

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

- PMLiVE

Allergan and taking a specialised approach

Pharma interview: Paul Navarre and Paul Boland talk about how the company, best known for Botox, is looking to create a culture of growth

- PMLiVE

Valeant takeover bid for Allergan turns hostile

Canadian firm goes directly to shareholders with offer

- PMLiVE

Allergan rebuffs Valeant once again

Could lead to hostile takeover bid

- PMLiVE

Valeant steps up pressure on Allergan with raised bid

Ups price yet again in attempt to acquire company behind Botox

- PMLiVE

Valeant sweetens Allergan offer with help from Nestle deal

Will divest skincare treatments to sidestep product conflict issues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links